Eterna Therapeutics Inc (ERNA) - Total Liabilities
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has total liabilities worth $3.12 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ERNA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Eterna Therapeutics Inc - Total Liabilities Trend (2006–2025)
This chart illustrates how Eterna Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Eterna Therapeutics Inc total assets.
Eterna Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Eterna Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Charger Metals NL
AU:CHR
|
Australia | AU$444.55K |
|
Mamba Exploration Ltd
AU:M24
|
Australia | AU$217.59K |
|
Blockmate Ventures Inc
V:MATE
|
Canada | CA$7.26 Million |
|
21st Century Management Services Limited
NSE:21STCENMGM
|
India | Rs64.99 Million |
|
Nigbas Nigde Beton Sanayi ve Ticaret AS
IS:NIBAS
|
Turkey | TL161.14 Million |
|
Sawang Export Public Company Limited
BK:SAWANG
|
Thailand | ฿37.47 Million |
|
Innity Corporation Bhd
KLSE:0147
|
Malaysia | RM39.63 Million |
|
NanoVibronix Inc
NASDAQ:NAOV
|
USA | $11.92 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Eterna Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Eterna Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eterna Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eterna Therapeutics Inc (2006–2025)
The table below shows the annual total liabilities of Eterna Therapeutics Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.43 Million | -3.78% |
| 2024-12-31 | $3.57 Million | -92.39% |
| 2023-12-31 | $46.90 Million | +361.06% |
| 2022-12-31 | $10.17 Million | +68.94% |
| 2021-12-31 | $6.02 Million | +14.75% |
| 2020-12-31 | $5.25 Million | -48.48% |
| 2019-12-31 | $10.19 Million | +28.16% |
| 2018-12-31 | $7.95 Million | -27.98% |
| 2017-12-31 | $11.03 Million | -15.56% |
| 2016-12-31 | $13.07 Million | +0.72% |
| 2015-12-31 | $12.97 Million | +14.38% |
| 2014-12-31 | $11.34 Million | +81.36% |
| 2013-12-31 | $6.25 Million | +31.35% |
| 2012-12-31 | $4.76 Million | -10.10% |
| 2011-12-31 | $5.30 Million | +44.57% |
| 2010-12-31 | $3.66 Million | -24.90% |
| 2009-12-31 | $4.88 Million | +24.59% |
| 2008-12-31 | $3.92 Million | -26.00% |
| 2007-12-31 | $5.29 Million | -33.81% |
| 2006-12-31 | $8.00 Million | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for… Read more